Henlius to Initiate P-III Study of HLX04-O (biosimilar, bevacizumab) in Australia
Henlius to Initiate P-III Study of HLX04-O (biosimilar, bevacizumab) in Australia
Shots:
- Henlius reported that TGA has approved the filing of clinical trial for HLX04-O to treat wet-AMD
- The two part P-III global study is expected to be initiated in Australia to further evaluate the efficacy & safety of HLX04-O (vitreous injection) in treatment of wAMD
- HLX04-O is a recombinant anti-VEGF humanized mAb ophthalmic injection and has the potential to be one of the first bevacizumab approved for ophthalmic diseases
Click here to read full press release/ article | Ref: Henlius | Image: Henlius
